NCT02649413

Brief Summary

The initial steroids dose for Nephrotic Syndrome is 60mg/1m2 for 6-4 weeks and the duration of the first steroid course is between 8 weeks to 6 months. The base of the initial dose for steroids Idiopathic nephrotic syndrome been put in the early 70s. In our study the investigators will adjusted the first steroids does to the response day. Our primary end point is : a lower adjusted dose is as good as the fix dose in the first year after diagnosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2016

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 31, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 7, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

March 1, 2016

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
Last Updated

January 12, 2016

Status Verified

December 1, 2015

Enrollment Period

3.1 years

First QC Date

December 31, 2015

Last Update Submit

January 11, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • The time until the first relapse

    All Children with Nephrotic Syndrome will start a dose of 60 mg/m2 prednisone.patients that will response in 8 days (the first day with a negative or trace in the urine deep stick test)will receive adjusted lower steroid dose.the outcome is the time until the first relapse( positive protein in deep stick urine test,or low serum albumin with positive urine deep stick).the control group is the historical data from a prospective malty center observation study.

    6 months

Secondary Outcomes (1)

  • Number of relapse during first year

    one year

Study Arms (1)

Early response to prednisone treatment

EXPERIMENTAL

intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.

Drug: Prednisone

Interventions

Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.

Also known as: corticosteroids
Early response to prednisone treatment

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Children who recently have been diagnosed with nephrotic syndrome.

You may not qualify if:

  • Children with nephrotic syndrome that can not be treated with steroids.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shneider children Hospital Nephrology Institute

Petah Tikva, Israel

Location

MeSH Terms

Conditions

Nephrosis, Lipoid

Interventions

PrednisoneAdrenal Cortex Hormones

Condition Hierarchy (Ancestors)

NephrosisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

PregnadienediolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • Amit Dagan, Dr.

    Shneider children Hospital Nephrology Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Amit Dagan, Dr.

CONTACT

Amit Dagan, Dr.

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 31, 2015

First Posted

January 7, 2016

Study Start

March 1, 2016

Primary Completion

April 1, 2019

Study Completion

June 1, 2019

Last Updated

January 12, 2016

Record last verified: 2015-12

Data Sharing

IPD Sharing
Will not share

Locations